{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:59:16Z","timestamp":1783382356022,"version":"3.54.6"},"reference-count":40,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.bulcan.2024.09.007","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T12:50:08Z","timestamp":1730983808000},"page":"1142-1153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effets ind\u00e9sirables cardiovasculaires sous inhibiteurs de la Bruton tyrosine kinase\u00a0: m\u00e9canismes physiopathologiques, d\u00e9pistage et prise en charge"],"prefix":"10.1016","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1284-8191","authenticated-orcid":false,"given":"Jennifer","family":"Cautela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyne","family":"Croizier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Inchiappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trecy","family":"Goncalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Stocker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Tchernonog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"41","key":"10.1016\/j.bulcan.2024.09.007_bib0205","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022\u00a0ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.bulcan.2024.09.007_bib0210","doi-asserted-by":"crossref","first-page":"e001049","DOI":"10.1136\/openhrt-2019-001049","article-title":"High incidence of atrial fibrillation in patients treated with ibrutinib","volume":"6","author":"Baptiste","year":"2019","journal-title":"Open Heart"},{"issue":"6","key":"10.1016\/j.bulcan.2024.09.007_bib0215","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3324\/haematol.2021.278901","article-title":"Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762\u00a0patients","volume":"107","author":"Brown","year":"2022","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.bulcan.2024.09.007_bib0220","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/hon.3126","article-title":"Predictors of ibrutinib-associated atrial fibrillation: 5-year follow-up of a prospective study","volume":"41","author":"Mattiello","year":"2023","journal-title":"Hematol Oncol"},{"issue":"33","key":"10.1016\/j.bulcan.2024.09.007_bib0225","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018\u00a0ESC\/ESH guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"issue":"22","key":"10.1016\/j.bulcan.2024.09.007_bib0230","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and incident cardiovascular events following ibrutinib initiation","volume":"134","author":"Dickerson","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2024.09.007_bib0235","doi-asserted-by":"crossref","first-page":"630942","DOI":"10.3389\/fcell.2021.630942","article-title":"Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects","volume":"9","author":"Estupi\u00f1\u00e1n","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"3","key":"10.1016\/j.bulcan.2024.09.007_bib0240","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/sji.12333","article-title":"Targets for ibrutinib beyond B cell malignancies","volume":"82","author":"Bergl\u00f6f","year":"2015","journal-title":"Scand J Immunol"},{"issue":"29","key":"10.1016\/j.bulcan.2024.09.007_bib0245","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765\u00a0blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"25","key":"10.1016\/j.bulcan.2024.09.007_bib0250","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling","volume":"124","author":"McMullen","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bulcan.2024.09.007_bib0255","doi-asserted-by":"crossref","first-page":"H713","DOI":"10.1152\/ajpheart.00273.2010","article-title":"Stress signaling by Tec tyrosine kinase in the ischemic myocardium","volume":"299","author":"Zhang","year":"2010","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"4","key":"10.1016\/j.bulcan.2024.09.007_bib0260","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1083\/jcb.152.4.717","article-title":"A specific role of phosphatidylinositol 3-kinase gamma. A regulation of autonomic Ca(2)+ oscillations in cardiac cells","volume":"152","author":"Bony","year":"2001","journal-title":"J Cell Biol"},{"issue":"13","key":"10.1016\/j.bulcan.2024.09.007_bib0265","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.2174\/1389450115666141114151911","article-title":"Trastuzumab-induced cardiotoxicity: is it a personalized risk?","volume":"15","author":"Milano","year":"2014","journal-title":"Curr Drug Targets"},{"issue":"13","key":"10.1016\/j.bulcan.2024.09.007_bib0270","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","article-title":"Cardiovascular toxicities associated with ibrutinib","volume":"74","author":"Salem","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.bulcan.2024.09.007_bib0275","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1161\/CIRCULATIONAHA.120.049210","article-title":"Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase","volume":"142","author":"Xiao","year":"2020","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.bulcan.2024.09.007_bib0280","doi-asserted-by":"crossref","first-page":"e1057385","DOI":"10.1080\/2162402X.2015.1057385","article-title":"Ibrutinib enhances IL-17\u00a0response by modulating the function of bone marrow derived dendritic cells","volume":"5","author":"Natarajan","year":"2016","journal-title":"Oncoimmunology"},{"issue":"24","key":"10.1016\/j.bulcan.2024.09.007_bib0285","doi-asserted-by":"crossref","first-page":"39218","DOI":"10.18632\/oncotarget.16836","article-title":"The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages","volume":"8","author":"Ping","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.bulcan.2024.09.007_bib0290","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/bjh.15080","article-title":"Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice","volume":"180","author":"Gribben","year":"2018","journal-title":"Br J Haematol"},{"issue":"26","key":"10.1016\/j.bulcan.2024.09.007_bib0295","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood-2014-06-583294","article-title":"Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions","volume":"124","author":"Levade","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bulcan.2024.09.007_bib0300","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/leu.2014.247","article-title":"Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation","volume":"29","author":"Kamel","year":"2015","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.bulcan.2024.09.007_bib0305","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1182\/bloodadvances.2019000640","article-title":"Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin \u03b1IIb\u03b23\u00a0in mice and humans","volume":"3","author":"Dobie","year":"2019","journal-title":"Blood Adv"},{"issue":"38","key":"10.1016\/j.bulcan.2024.09.007_bib0310","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1093\/eurheartj\/ehab362","article-title":"Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study","volume":"42","author":"Salem","year":"2021","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.bulcan.2024.09.007_bib0315","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s10840-022-01400-z","article-title":"Tyrosine kinase inhibitor\u2013associated ventricular arrhythmias: a case series and review of literature","volume":"66","author":"Fazal","year":"2023","journal-title":"J Interv Card Electrophysiol"},{"issue":"31","key":"10.1016\/j.bulcan.2024.09.007_bib0320","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1200\/JCO.21.00693","article-title":"Cardiovascular risk associated with ibrutinib use in chronic lymphocytic leukemia: a population-based cohort study","volume":"39","author":"Abdel-Qadir","year":"2021","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.bulcan.2024.09.007_bib0325","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.bulcan.2024.09.007_bib0330","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood-2018-08-870238","article-title":"Long-term follow-up of the RESONATE phase 3\u00a0trial of ibrutinib vs ofatumumab","volume":"133","author":"Byrd","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bulcan.2024.09.007_bib0335","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.bulcan.2024.09.007_bib0340","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv"},{"issue":"10232","key":"10.1016\/j.bulcan.2024.09.007_bib0345","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3\u00a0trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.bulcan.2024.09.007_bib0350","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.19.03355","article-title":"ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"38","author":"Ghia","year":"2020","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.bulcan.2024.09.007_bib0355","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2024.09.007_bib0360","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3\u00a0trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2024.09.007_bib0365","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.bulcan.2024.09.007_bib0370","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s44228-022-00015-5","article-title":"FIRE study: real-world effectiveness and safety of ibrutinib in clinical practice in patients with CLL and MCL","volume":"4","author":"Dartigeas","year":"2022","journal-title":"Clin Hematol Int"},{"issue":"12","key":"10.1016\/j.bulcan.2024.09.007_bib0375","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1016\/j.clml.2021.07.022","article-title":"Real-world characteristics and outcome of patients treated with single-agent ibrutinib for chronic lymphocytic leukemia in Spain (IBRORS-LLC study)","volume":"21","author":"Abrisqueta","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.bulcan.2024.09.007_bib0380","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/jha2.638","article-title":"A real-world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first-line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States","volume":"4","author":"Mato","year":"2023","journal-title":"EJHaem"},{"issue":"5","key":"10.1016\/j.bulcan.2024.09.007_bib0385","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/ejh.14072","article-title":"Incidence of cardiovascular and bleeding events and reasons for discontinuation in patients with chronic lymphocytic leukemia treated with ibrutinib-A retrospective analysis on consecutive patients from a well-defined region","volume":"111","author":"Andersson","year":"2023","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.bulcan.2024.09.007_bib0390","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-022-01302-7","article-title":"Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation","volume":"15","author":"Chen","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"20","key":"10.1016\/j.bulcan.2024.09.007_bib0395","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1182\/blood.2022016953","article-title":"Ventricular arrhythmias and sudden death events following acalabrutinib initiation","volume":"140","author":"Bhat","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bulcan.2024.09.007_bib0200","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/ejhf.654","article-title":"2016\u00a0ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"19","author":"Zamorano","year":"2017","journal-title":"Eur J Heart Fail"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455124003643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455124003643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T14:06:59Z","timestamp":1733407619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455124003643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0007455124003643"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2024.09.007","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effets ind\u00e9sirables cardiovasculaires sous inhibiteurs de la Bruton tyrosine kinase\u00a0: m\u00e9canismes physiopathologiques, d\u00e9pistage et prise en charge","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2024.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}